CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1
Sign Up to like & getrecommendations! Published in 2020 at "Signal Transduction and Targeted Therapy"
DOI: 10.1038/s41392-020-00375-5
Abstract: Sorafenib is the first-line chemotherapeutic therapy for advanced hepatocellular carcinoma (HCC). However, sorafenib resistance significantly limits its therapeutic efficacy, and the mechanisms underlying resistance have not been fully clarified. Here we report that a circular… read more here.
Keywords: circrna sore; resistance; hcc; sorafenib resistance ... See more keywords